Overview

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
Phase:
PHASE1
Details
Lead Sponsor:
Vigonvita Life Sciences